NCT05824325View on ClinicalTrials.gov

Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

March 14, 2023

Primary Completion Date

April 10, 2025

Study Completion Date

October 10, 2026

Conditions

Breast Cancer

Interventions

DRUG

SHR-A1811

HER2 ADC

DRUG

TROP2 ADC

TROP2 ADC

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER